Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 all comers meta-analysis

sarilumab phase 2 high dose unpublished
 
NCT04315298
RCTsarilumab high dose (400mg)placeboCOVID 19 all comershigh
145/77 suggested -19% 98% -55%
sarimulab phase 2 low dose unpublished
 
NCT04315298
RCTsarilumab low dose (200mg)placeboCOVID 19 all comershigh
136/77 suggested 46% 46% -27%

COVID-19 severe or critically meta-analysis

REMAP-CAP sarilumab, 2021
 
NCT02735707
RCTsarilumabstandard of careCOVID-19 severe or criticallysome concern
48/402 conclusif -44% demonstrated68%
ARI-RAF (Della-Torre), 2020 OBSsarilumabcontrolCOVID-19 severe or criticallyNA
28/28 inconclusive -58%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).